amifostine anhydrous has been researched along with Cancer of Ovary in 32 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ninety ovarian cancer patients were randomized to receive standard paclitaxel + carboplatin without (PC) or preceded by amifostine 740 mg/m(2) (PC + A)." | 2.71 | A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. ( Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH, 2005) |
| "Topotecan was given as a 30-min IV infusion." | 2.70 | No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ( Malmström, H; Peterson, C; Zackrisson, AL, 2002) |
| "Twenty patients with advanced ovarian cancer were treated with chemotherapy PC (cisplatin 100 mg/m2, cyclophosphamide 1000 mg/m2) administered with amifostine." | 2.69 | [Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer]. ( Pawlicki, M; Rolski, J; Rychlik, U; Wiczyńska, B, 1998) |
| "Amifostine (Ethyol) administered to cancer patients is rapidly cleared from plasma by a biphasic decay with an alpha half-life (T1/2 alpha) of 0." | 2.39 | Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. ( Korst, AE; van der Vijgh, WJ, 1996) |
| " Our results confirm previous reports of the ability of amifostine to protect normal tissues from the toxic effects of chemotherapy drugs and now extend these observations to paclitaxel." | 1.30 | Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. ( Capizzi, RL; Fernandes, D; Johnson, CS; List, AF; Paine-Murrieta, GD; Taylor, CW; Wang, LM, 1997) |
| "For a model of advanced ovarian cancer, mice received tumor cell injections on day 0 and did not begin drug treatment until tumors were palpable (0." | 1.29 | Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. ( Capizzi, RL; Johnson, CS; Lopez, MH; Paine, GD; Taylor, CW, 1996) |
| " Selectivity of protection by WR2721 is probably due to the preferential formation and uptake of the thiol metabolite 2-(3-aminopropylamino)ethanethiol (WR1065), which can inactivate toxic platinum-species inside the cell." | 1.28 | Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse. ( Boven, E; Holwerda, U; Pinedo, HM; Treskes, M; van der Vijgh, WJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 22 (68.75) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouhadjari, N | 1 |
| Gabato, W | 1 |
| Calabrese, D | 1 |
| Msika, S | 1 |
| Keita, H | 1 |
| Berry, E | 1 |
| Matthews, KS | 1 |
| Singh, DK | 1 |
| Buttin, BM | 1 |
| Lurain, JR | 1 |
| Alvarez, RD | 1 |
| Schink, J | 1 |
| Lorusso, D | 1 |
| Ferrandina, G | 1 |
| Greggi, S | 1 |
| Gadducci, A | 1 |
| Pignata, S | 1 |
| Tateo, S | 1 |
| Biamonte, R | 1 |
| Manzione, L | 1 |
| Di Vagno, G | 1 |
| Ferrau', F | 1 |
| Scambia, G | 1 |
| De Vos, FY | 1 |
| Bos, AM | 1 |
| Schaapveld, M | 1 |
| de Swart, CA | 1 |
| de Graaf, H | 1 |
| van der Zee, AG | 1 |
| Boezen, HM | 1 |
| de Vries, EG | 1 |
| Willemse, PH | 1 |
| Hilpert, F | 1 |
| Stähle, A | 1 |
| Tomé, O | 1 |
| Burges, A | 1 |
| Rossner, D | 1 |
| Späthe, K | 1 |
| Heilmann, V | 1 |
| Richter, B | 1 |
| du Bois, A | 1 |
| Alberts, DS | 1 |
| Delforge, A | 1 |
| Capizzi, RL | 5 |
| Treskes, M | 2 |
| Boven, E | 5 |
| van de Loosdrecht, AA | 1 |
| Wijffels, JF | 1 |
| Cloos, J | 1 |
| Peters, GJ | 1 |
| Pinedo, HM | 3 |
| van der Vijgh, WJ | 6 |
| Kemp, G | 1 |
| Rose, P | 1 |
| Lurain, J | 1 |
| Berman, M | 1 |
| Manetta, A | 1 |
| Roullet, B | 1 |
| Homesley, H | 1 |
| Belpomme, D | 1 |
| Glick, J | 1 |
| Paine, GD | 1 |
| Taylor, CW | 2 |
| Lopez, MH | 1 |
| Johnson, CS | 2 |
| Rose, PG | 1 |
| Facchini, T | 1 |
| Korst, AE | 3 |
| van der Sterre, ML | 2 |
| Fichtinger-Schepman, AM | 2 |
| Wang, LM | 1 |
| List, AF | 1 |
| Fernandes, D | 1 |
| Paine-Murrieta, GD | 1 |
| Dranitsaris, G | 1 |
| Shapiro, JD | 1 |
| Rothenberg, ML | 1 |
| Sarosy, GA | 1 |
| Steinberg, SM | 1 |
| Adamo, DO | 1 |
| Reed, E | 1 |
| Ozols, RF | 1 |
| Kohn, EC | 1 |
| Pawlicki, M | 1 |
| Rolski, J | 1 |
| Wiczyńska, B | 1 |
| Rychlik, U | 1 |
| Longo, CJ | 1 |
| Lindemann, K | 1 |
| Garzetti, GG | 1 |
| Ciavattini, A | 1 |
| Muzzioli, M | 1 |
| Romanini, C | 1 |
| Calhoun, EA | 1 |
| Bennett, CL | 1 |
| Ng, TY | 1 |
| Ngan, HY | 1 |
| Cheng, DK | 1 |
| Wong, LC | 1 |
| Nagy, P | 1 |
| Kádasi, L | 1 |
| Verschraagen, M | 1 |
| Hulscher, TM | 1 |
| Erkelens, CA | 1 |
| Hausheer, FH | 1 |
| Zackrisson, AL | 1 |
| Malmström, H | 1 |
| Peterson, C | 1 |
| Hamers, F | 1 |
| Neijt, J | 1 |
| Gispen, W | 1 |
| Holwerda, U | 1 |
| Niibe, H | 1 |
| Takahashi, I | 1 |
| Miyaishi, K | 1 |
| Mitsuhashi, N | 1 |
| Maehara, Y | 1 |
| Nakajima, N | 1 |
| Suto, H | 1 |
| Saito, Y | 1 |
| Yamakawa, M | 1 |
| Sugiyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma[NCT00003322] | Phase 3 | 384 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for amifostine anhydrous and Cancer of Ovary
| Article | Year |
|---|---|
Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug-Related S | 2006 |
Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Female; Humans; Male; Ne | 1994 |
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cisplatin; DNA Adducts; Drug Administration | 1996 |
Clinical status and optimal use of amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Bone Marrow Cells; Clinical Trials, Phase III as Topic; | 1999 |
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Topics: Amifostine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1999 |
11 trials available for amifostine anhydrous and Cancer of Ovary
| Article | Year |
|---|---|
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infu | 2003 |
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free S | 2005 |
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AG
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; | 2005 |
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1996 |
Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cyclophosphamide | 1996 |
Advances in supportive therapy.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Female; Hum | 1996 |
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclo | 1998 |
[Evaluation of efficacy and toxicity of PC chemotherapy (cisplatin, cyclophosphamide) administered with amifostine in patients with clinically advanced ovarian cancer].
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide | 1998 |
Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; C | 1999 |
No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Area Under Curve; Chromatography, High Pressure Liqu | 2002 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
16 other studies available for amifostine anhydrous and Cancer of Ovary
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy P | 2016 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
Topics: Amifostine; Animals; Bone Marrow; Carboplatin; Cell Division; Dose-Response Relationship, Drug; Drug | 1994 |
Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combin | 1996 |
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Body Temperature; Carboplatin; DNA Adducts; Drug Adminis | 1997 |
Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Topics: Amifostine; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Culture | 1997 |
A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Agents; Attitude to Health; Canada; Cost Savings; Cost | 1997 |
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Combinations; Drug Synergism; Female; Hu | 1998 |
Choices of methodology in pharmacoeconomics studies.
Topics: Amifostine; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Canada; Cisplatin; Cost | 1999 |
Administration of the cytoprotectant amifostine.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Kidney | 1998 |
Pharmacoeconomics of amifostine in ovarian cancer.
Topics: Amifostine; Antineoplastic Agents; Canada; Cost-Benefit Analysis; Cytoprotection; Female; Humans; Mo | 1999 |
The effect of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines.
Topics: Amifostine; Antineoplastic Agents; Carcinoma; Drug Interactions; Female; Humans; Ovarian Neoplasms; | 1999 |
[Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; | 2000 |
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cell Division; Cisplatin; Drug Interactions | 2002 |
Protection of cisplatin-induced neuropathy: recent developments.
Topics: Adrenocorticotropic Hormone; Amifostine; Anticonvulsants; Cisplatin; Female; Glutathione; Humans; Ne | 1992 |
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Topics: Amifostine; Animals; Cisplatin; Drug Administration Schedule; Female; Kidney; Liver; Male; Mannitol; | 1992 |